Work

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.07.015

Authors: Krishnansu S. Tewari, Michael W. Sill, Robert L. Coleman, Carol Aghajanian, Robert Mannel, Paul A. DiSilvestro, Matthew Powell, Leslie M. Randall, John Farley, Stephen C. Rubin, Bradley J. Monk

Institutions: University of California, Irvine, Roswell Park Comprehensive Cancer Center, NRG Oncology, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Women & Infants Hospital of Rhode Island, Barnes-Jewish Hospital, Washington University in St. Louis, Creighton University, St. Joseph's Hospital and Medical Center, Fox Chase Cancer Center, The US Oncology Network, University of Arizona College of Medicine- Phoenix

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1291646684, G2304223924, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, NRG Oncology Network Group Operations Center, G434901823, G620050225, Cancer Center Support Grant

OpenAlex ID: W3043846144

FWCI: 0.903

Cites: 40

Cited by: 8

Related to: 10